Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Date:1/4/2008

ed Mr. Sekhri. "We are extremely pleased to have Matt join us as a member of our senior management team and believe he will contribute greatly to our efforts of building a pipeline of products aligned with our corporate strategy."

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation, and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe ulcerative colitis in the first quarter of 2007. Cerimon's topical patch formulation of diclofenac sodium completed a Phase I study in the fourth quarter of 2007. This study will rapidly be followed by two Phase II/III studies for the treatment of acute musculoskeletal pain.

The Company is well-financed, having closed a $70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/29/2015)... ... ... Nearly everyone has heard of the potential of stem cells to treat ... of these cells is teeth—baby teeth that come loose during childhood, wisdom teeth extracted ... room for braces. These potent stem cells exist in the dental pulp of ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Toothâ„¢ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2